Trial site

Heilongjiang Provincial Hospital

Harbin, 150030, ChinaNot linked to an institution yet

12running trials
5closed trials

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions: Type 2 diabetes3 trials
Ulcerative colitis3 trials
Coronary artery disease2 trials
Psoriasis2 trials
Atopic dermatitis (eczema)1 trial
Atrial fibrillation1 trial
Crohn's disease1 trial
Familial hypercholesterolaemia1 trial
Fatty liver disease (MASLD/MASH)1 trial
Heart failure1 trial
Hepatitis B1 trial
Liver and biliary tract cancer1 trial
and 2 more
Phase: Phase 37 trials
Phase 22 trials
Phase 42 trials
Phase 11 trial
Status: Completed5 trials
Recruiting5 trials
Not yet recruiting4 trials
Active, not recruiting2 trials
Enrolling by invitation1 trial
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.3 trials
Eli Lilly and Company2 trials
Beijing Hospital1 trial
Daiichi Sankyo1 trial
Harbin Medical University1 trial
and 9 more

Running trials

Recruiting
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
NCT07724366· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Xiguang Liu, Bachelor
Recruiting
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
NCT07687186· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source
Contact: Guimin Wang
Enrolling by invitation
Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
NCT07658417· Novo Nordisk A/S· Source
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· Phase 2· Eli Lilly and Company· Source
Contact: Xiaomei Sun (principal investigator)
Recruiting
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235· Phase 4· Shanghai Zhongshan Hospital· Source
Contact: Fuman Du
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593· Phase 3· Eli Lilly and Company· Source
Contact: weimin wang (principal investigator)
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Xiaoli Hu
Recruiting
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT06754891· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Xiaomei Sun, Doctor
Not yet recruiting
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
NCT06606509· Nanjing First Hospital, Nanjing Medical University· Source
Contact: Binhong Duan, Doctor
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Recruiting
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
NCT03987308· Beijing Hospital· Source
Contact: Binhong Duan, M.D, Ph.D.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Type 2 diabetes3 recruiting
Ulcerative colitis2 recruiting
Coronary artery disease1 recruiting
Crohn's disease1 recruiting
Heart failure1 recruiting
Hepatitis B1 recruiting
Liver and biliary tract cancer1 recruiting
Peripheral artery disease1 recruiting
Psoriasis1 recruiting
Type 1 diabetes1 recruiting

Closed trials

Completed
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Completed
Treatment of Moderate to Severe Plaque Psoriasis
NCT06542614· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Completed
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT05142722· Phase 3· NewAmsterdam Pharma· Source
Completed
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
NCT04747496· Daiichi Sankyo· Source
Completed
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
NCT04624854· Phase 4· Harbin Medical University· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error